We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+55.06%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.8B
AUM Growth
+$694M
Cap. Flow
+$99M
Cap. Flow %
3.54%
Top 10 Hldgs %
54.31%
Holding
75
New
7
Increased
22
Reduced
25
Closed
5

Top Buys

1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$63.5M
2
IMNM icon
Immunome
IMNM
+$32.3M
3
BHVN icon
Biohaven
BHVN
+$28.8M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$27.9M
5
ABT icon
Abbott
ABT
+$26.5M

Top Sells

1
KRYS icon
Krystal Biotech
KRYS
+$30M
2
HUM icon
Humana
HUM
+$29.1M
3
ELV icon
Elevance Health
ELV
+$28.8M
4
FOLD
Amicus Therapeutics
FOLD
+$24M
5
DXCM icon
DexCom
DXCM
+$22.8M

Sector Composition

1 Healthcare 94.12%
2 Industrials 3.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
51
DELISTED
Allakos
ALLK
$10M 0.36%
3,670,447
-464,614
-11% -$1.05M
ACIU icon
52
AC Immune
ACIU
$224M
$10M 0.36%
+2,000,000
New +$6.43M
RAPT
53
DELISTED
RAPT Therapeutics
RAPT
$9.11M 0.33%
45,847
-7,589
-14% -$939K
STXS icon
54
Stereotaxis
STXS
$154M
$5.95M 0.21%
3,402,443
-2,363,349
-41% -$3.82M
IVVD icon
55
Invivyd
IVVD
$219M
$5.68M 0.2%
1,440,725
– –
SNCE
56
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$5.29M 0.19%
990,412
– –
ATRA icon
57
Atara Biotherapeutics
ATRA
$75.6M
$4.67M 0.17%
364,258
+113,025
+45% +$2.64M
NUVB icon
58
Nuvation Bio
NUVB
$2.02B
$4.58M 0.16%
3,031,009
– –
LVTX
59
DELISTED
LAVA Therapeutics
LVTX
$3.28M 0.12%
2,074,372
– –
MDVL
60
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$3.05M 0.11%
692,082
– –
XERS icon
61
Xeris Biopharma Holdings
XERS
$1.52B
$2.46M 0.09%
1,046,587
– –
ACHL
62
DELISTED
Achilles Therapeutics
ACHL
$1.43M 0.05%
1,608,089
– –
KLRS
63
Kalaris Therapeutics
KLRS
$104M
$1.3M 0.05%
82,955
– –
SLGC
64
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$938K 0.03%
370,839
-28,600
-7% -$66.6K
NVTA
65
DELISTED
Invitae Corporation
NVTA
$924K 0.03%
1,474,026
-806,377
-35% -$482K
HOOK
66
DELISTED
HOOKIPA Pharma
HOOK
$862K 0.03%
106,377
– –
TKNO icon
67
Alpha Teknova
TKNO
$291M
$601K 0.02%
161,005
-123,559
-43% -$305K
ADAP
68
DELISTED
Adaptimmune Therapeutics
ADAP
$567K 0.02%
715,607
– –
VTYX
69
DELISTED
Ventyx Biosciences
VTYX
$512K 0.02%
207,203
-722,697
-78% -$6.86M
BCEL
70
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$58.4K ﹤0.01%
442,653
– –
DXCM icon
71
DexCom
DXCM
$29.6B
– –
-244,391
Closed -$22.8M
HUM icon
72
Humana
HUM
$48B
– –
-59,851
Closed -$29.1M
XENE icon
73
Xenon Pharmaceuticals
XENE
$6.6B
– –
-419,568
Closed -$14.3M
CUTR
74
DELISTED
Cutera, Inc.
CUTR
– –
-334,996
Closed -$2.02M
SONX
75
DELISTED
Sonendo, Inc.
SONX
– –
-410,393
Closed -$306K
1 2
3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q4 2023 Portfolio in Review

As of Q4 2023, Redmile Group held 75 positions worth $2.8B, up 33% from $2.1B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Redmile Group deployed $99M of net new capital in Q4 2023, opening 7 new positions and adding to 22 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Krystal Biotech, an estimated $30M trimmed.

  • Redmile Group's largest Q4 2023 buy was State Street SPDR S&P 500 ETF Trust: 142,500 shares worth $67.7M.
  • Redmile Group added most to Biohaven in Q4 2023, an estimated $28.8M increase.
  • Redmile Group's biggest Q4 2023 reduction was Krystal Biotech, cutting an estimated $30M.
  • Redmile Group fully exited Humana in Q4 2023, selling an estimated $29.1M.
  • Redmile Group's ten largest holdings make up 54% of its $2.8B portfolio in Q4 2023.
  • Redmile Group opened 7 new positions and closed 5 in Q4 2023.
  • Redmile Group's portfolio value rose 33% quarter-over-quarter to $2.8B.

Based on Redmile Group's 13F filing for Q4 2023, filed 14 Feb 2024.